Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
Liver Cancer
|
November 11, 2024
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Keiichi Akahoshi, Junichi Shindoh, Minoru Tanabe, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Internal Medicine (Tokyo, Japan)
|
September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
Kayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Internal Medicine (Tokyo, Japan)
|
September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
Nozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Oncology
|
November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment
Daiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 17, 2020
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
Yorinari Ochiai, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer
|
January 14, 2021
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Annals of Surgery
|
May 27, 2017
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Kristoffer W Brudvik, Robert P Jones, Felice Giuliante, et al.
Journal of Hepato-Biliary-Pancreatic Sciences
|
December 1, 2020
Assembling a library of typical surgery video clips to construct a system for assessing the surgical difficulty of laparoscopic cholecystectomy
Masanao Kurata, Yukio Iwashita, Tetsuji Ohyama, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
Liver Cancer
|
November 11, 2024
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Keiichi Akahoshi, Junichi Shindoh, Minoru Tanabe, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Internal Medicine (Tokyo, Japan)
|
September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
Kayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Internal Medicine (Tokyo, Japan)
|
September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
Nozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Oncology
|
November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment
Daiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 17, 2020
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
Yorinari Ochiai, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer
|
January 14, 2021
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Annals of Surgery
|
May 27, 2017
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Kristoffer W Brudvik, Robert P Jones, Felice Giuliante, et al.
Journal of Hepato-Biliary-Pancreatic Sciences
|
December 1, 2020
Assembling a library of typical surgery video clips to construct a system for assessing the surgical difficulty of laparoscopic cholecystectomy
Masanao Kurata, Yukio Iwashita, Tetsuji Ohyama, et al.
Page
of 18